Neuraxis

NRXS

Market cap $31M

NRXS reports strong second-quarter 2025 revenue growth and lower losses, but gross margin compression remains a key concern.

NeurAxis, Inc. (NYSE:NRXS ) Q2 2025 Earnings Conference Call August 12, 2025 9:00 AM ET Company Participants Brian Carrico - President, CEO & Director Timothy Robert Henrichs - Chief Financial Officer Conference Call Participants Ben Shamsian - Unidentified Company Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Lindsay Leeds - Unidentified Company Operator Good day, everyone, and welcome to the NeurAxis Report Second Quarter 2025 Financial Results. [Operator Instructions] Please note that this conference is being recorded.

CARMEL, Ind., June 17, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), covering two health insurers, with approximately 700,000 total members in Connecticut and Massachusetts. This medical policy will bring our national total coverage for PENFS to roughly 53 million, with more decisions from major payers still pending.

CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the closing of its previously announced registered direct offering of 1,538,461 shares of its common stock at a purchase price of $3.25 per share.

CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,538,461 shares of its common stock at a purchase price of $3.25 per share in a registered direct offering priced at the market under NYSE American rules.

NRXS posts strong first-quarter 2025 earnings with robust revenue growth and FDA milestones, driving stock gains as investors eye broader insurance coverage and market expansion.

NeurAxis, Inc. (NYSE:NRXS ) Q1 2025 Earnings Conference Call May 12, 2025 9:00 AM ET Company Participants Ben Shamsian - IR Brian Carrico - President, CEO & Director Tim Henrichs - CFO Brian Carrico - President, CEO & Director Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the NeurAxis First Quarter 2025 Results and Update Call.

CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025.

Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time

NRXS records strong revenue growth, expanded insurance coverage and new FDA clearances in fourth-quarter 2024.